22 results about "HER2 Antibody" patented technology

The present application relates to the technical field of antibodies, in particular to HER2 antibodies or antigen-binding fragments thereof. The present application provides HER2 antibodies or antigen-binding fragments thereof, wherein the heavy chain comprises at least one mutation: CDR1 is mutated to T5M in the wild-type fragment of SEQ ID NO. 1, D6G mutation, or CDR2 is mutated to G7V in the wild-type fragment of SEQ ID NO. 2. The antibody has high affinity to HER2 S310F / Y The mutant target has the recognition ability and maintains the functional activity to the wild-type HER2.

A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the ATR inhibitor are administered in combination to a subject: Formula (I):

This disclosure pertains to the field of biomedicine and relates to the use of an anti-HER2 antibody-drug conjugate (ADC) for the treatment of breast cancer. It also relates to a method for treating a subject with breast cancer, the method comprising administering an anti-HER2 antibody-drug conjugate to the subject. Furthermore, it relates to the use of the anti-HER2 antibody-drug conjugate in the preparation of a medicament for neoadjuvant therapy of breast cancer. The method provides benefit to breast cancer subjects and has a good safety profile.

The application belongs to the field of biological medicine, and relates to the use of an anti-HER2 antibody drug conjugate for treating breast cancer. The application also relates to the use of an anti-HER2 antibody drug conjugate in the preparation of a medicament for treating breast cancer in a subject. The application also relates to a method for treating breast cancer in a subject, which comprises administering an anti-HER2 antibody drug conjugate to the subject. The method is beneficial to the breast cancer subject, and has good safety.

A pharmaceutical product for administration of an anti- HER2 antibody-drug conjugate (ADC) in combination with an anti-TROP2 ADC is provided. The anti-HER2 ADC and the anti-TROP2 ADC comprise a drug-linker. An exatecan may be the drug of the drug-linker and the drug-linker may be conjugated to the respective antibody via a thioether bond. Also provided is a therapeutic use and method in which the anti-HER2 ADC and the anti-TROP2 ADC are administered in combination to a subject. The anti-HER2 ADC and anti-TROP2 ADC in combination have excellent anti-cancer properties.

The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Provided herein are methods for treating or preventing progression of cervical cancer in an individual, including administering to the individual an effective amount of an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that comprises an anti-HER2 antibody and a cytotoxic molecule. Also provided herein are methods for treating or preventing progression of cervical cancer in an individual, including administering to the individual an effective amount of an anti-HER2 antibody-drug conjugate that includes an anti-HER2 antibody and a cytotoxic molecule, in combination with an anti-PD-1 antibody. Also provided herein are uses of an anti-HER2 antibody-drug conjugate, or an anti-HER2 antibody drug conjugate in combination with an anti-PD-1 antibody, for manufacture of a medicament for treating or preventing progression of a previously treated cervical cancer in an individual. Also provided herein are pharmaceutical compositions for use in treating a previously treated cervical cancer in an individual.

This disclosure relates to anti-HER2 antibodies or antigen binding fragments thereof, anti-TROP2 antibodies or antigen binding fragments thereof, antigen-binding protein constructs (e.g., bispecific antibodies or antigen-binding fragments thereof) that specifically bind to two different antigens (e.g., HER2 and TROP2), and antibody drug conjugates.

In one embodiment, the present invention relates to an anti-HER2 immunoglobulin E (IgE) antibody for use in the treatment of tumors with low HER2 expression in a subject. In another embodiment, the present invention provides an immunoglobulin that binds to HER2.

Provided are a pharmaceutical combination of an anti-HER3 antibody-drug conjugate and an anti-HER2 antibody, and a use of the pharmaceutical combination for treating cancer. The drug combination has good safety, has stronger anti-tumor efficacy than a single drug, and exhibits a synergistic tumor-inhibitory effect. Also provided is a kit comprising the pharmaceutical combination.

The invention relates to application of a combination of decitabine and an anti-HER2 antibody in preparation of a medicine for treating tumors. The invention provides application of decitabine or an analogue thereof in preparation of a medicine for treating tumors in combination with an anti-HER2 (Human Epidermal Growth Factor Receptor 2) antibody. The invention also provides application of decitabine or an analogue thereof, an anti-HER2 antibody and one, more or all of a cell aging induction medicine, a ZBP1 agonist and an SETDB1 inhibitor in preparation of medicines for treating tumors. The present invention also provides pharmaceutical compositions and kits comprising decitabine or an analog thereof and an anti-HER2 antibody.

A pharmaceutical product is provided for combined administration of an antibody-drug conjugate and an anti-PD-1 / TIM-3 bispecific binding protein. The antibody-drug conjugate is an antibody-drug conjugate wherein a drug-linker represented by the following formula (where A represents the linking position with the antibody) is conjugated to an antibody via a thioether bond, specifically an anti-TROP2 or anti-HER2 antibody. A therapeutic use and method are also provided, wherein the antibody-drug conjugate and the anti-PD-1 / TIM-3 bispecific binding protein are administered in combination to a subject.

Provided herein are methods for treating or preventing progression of cancer in an individual, comprising administering to the individual an effective amount of an anti-PD-1 antibody, e.g., toripalimab, and an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that comprises an anti-HER2 antibody and a cytotoxic molecule. Compositions, uses, and kits related thereto are also provided.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The present invention relates to the use of an anti-HER2 antibody-drug conjugate (ADC) in preparing a drug for treating urothelial carcinoma. The drug is safe and effective for patients with urothelial carcinoma, especially locally advanced or metastatic urothelial carcinoma, and can effectively prolong the survival time of the patients.

There are provided pharmaceutical products for the combined administration of an anti-HER2 antibody-drug conjugate and a PARP1 selective inhibitor. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (where A represents the position of linkage to the antibody) is conjugated to the anti-HER2 antibody via a thioether bond. There are also provided therapeutic uses and methods in which the antibody-drug conjugate and the PARP1 selective inhibitor are administered in combination to a subject: Formula (I)

The application belongs to the field of biological medicine, and particularly relates to a HER2 antibody, a pharmaceutical composition and application thereof. The application provides an antibody binding to HER2, which comprises a first antigen binding part and a second antigen binding part, the first antigen binding part comprises an anti-HER2 nanobody, and the sequence of the anti-HER2 nanobody comprises an amino acid sequence as shown in any one of SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8, and the second antigen binding part comprises trastuzumab or pertuzumab. The antibody provided by the application has the effect of inhibiting HER2 related tumors, the bispecific antibody in the antibody can specifically recognize different epitopes of HER2, inhibit non-ligand dependent and ligand dependent HER2 positive tumor cell proliferation, has obvious inhibiting effect on HER2 positive tumors and HER2 low expression tumors resistant to trastuzumab, and provides a new scheme for diagnosis and treatment of HER2 related tumors.

This provides a novel therapeutic agent that can target HER2 in the brain parenchyma, transcending the blood-brain barrier (BBB). [Solution] In some embodiments, anti-HER2 constructs (e.g., Fc polypeptide dimer-antibody variable region fusion proteins) retain effector function upon binding to HER2 but do not substantially reduce reticulocytes in vivo. The disclosure also relates to methods for transcytosis of anti-HER2 antibody variable regions across the blood-brain barrier to treat HER2-positive cancers and their metastatic lesions.

The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

Combination therapy with trastuzumab, a second anti-HER2 antibody, and a chemotherapy agent (XELOX) extends the progression-free survival (PFS) and / or overall survival (OS) of patients compared to the existing first-line treatment regimen for HER2-positive advanced gastric cancer.